Head-to-head comparisons of the peptides and GLP-1s readers ask about most. Editorial calls grounded in real trials, FDA labels, and PMIDs. Plain English, no marketing.
Tirzepatide loses more weight and drops A1C harder in head-to-head trials, but it costs more, hits the gut harder for some people, and has a shorter track record. Semaglutide is the easier on-ramp; tirzepatide is the heavier hitter.
COMPARISONMounjaro and Wegovy are different molecules sold under different brand names. Mounjaro (tirzepatide) is FDA-approved for diabetes; Zepbound is the same molecule for weight loss. Wegovy (semaglutide) is approved for weight loss; Ozempic is the same molecule for diabetes. Mounjaro/Zepbound loses more weight in head-to-head data; Wegovy is cheaper and more available.
COMPARISONBoth are research peptides with no human RCTs. BPC-157 has the deeper animal-study record for gut and tendon healing. TB-500 has stronger animal-study support for systemic soft-tissue and ligament work. Most operators run them together for 4 to 6 weeks rather than choosing - that's the Wolverine Blend.
COMPARISONOral BPC-157 works for gut healing - that's where the molecule originated, and it's stable in stomach acid. Subcutaneous injection is the protocol the rat tendon studies used; if a reader has tendon, ligament, or musculoskeletal work, injection is the route with the actual animal evidence behind it.
COMPARISONThese two peptides do different jobs and most operators run them together. CJC-1295 increases the height of growth hormone pulses; ipamorelin increases the frequency. Solo, ipamorelin is the cleaner molecule with fewer side effects. The standard biohacker stack is CJC-1295 (no DAC) plus ipamorelin in a single subQ shot.
COMPARISONDAC (Drug Affinity Complex) extends CJC-1295's half-life from minutes to about 6-8 days. The no-DAC form (also sold as Mod-GRF 1-29) gives natural pulsatile GH release; the DAC form gives a steady GH bleed. Most operators want pulses - that's why no-DAC plus ipamorelin is the standard stack. DAC is the simpler protocol if missing daily injections is the issue.
COMPARISONTirzepatide is FDA-approved and available now. Retatrutide is in Phase 3 trials (TRIUMPH-3 read out in 2025) showing about 24% body weight loss at 48 weeks, but it is not yet approved or commercially available in 2026. If a reader needs to start losing weight today, the answer is tirzepatide.
COMPARISONCerebrolysin is a porcine-brain-derived neuropeptide cocktail used clinically for stroke and TBI recovery in Europe and Russia, with the CARS and CAPTAIN trials behind it. Semax is a synthetic 7-amino-acid ACTH fragment used as a Russian-approved nasal spray for cognitive support and stroke. Cerebrolysin has stronger trial evidence for major neurological events; Semax is the easier daily-use cognitive nootropic.
COMPARISONBoth Vyleesi and Addyi are FDA-approved for premenopausal HSDD (low sexual desire), but they work differently. Vyleesi (bremelanotide / PT-141) is an on-demand subQ injection taken before sex. Addyi (flibanserin) is a daily oral pill that requires weeks of buildup and full alcohol avoidance. Vyleesi is the easier protocol for most women - on-demand, no daily commitment, no alcohol restriction.
COMPARISONTopical GHK-Cu is the form with actual skin and hair clinical evidence behind it - it's been in cosmetic dermatology for decades. Injectable GHK-Cu is a research-use protocol with thinner human evidence; most operators using GHK-Cu for systemic anti-aging effects are extrapolating from animal data and Pickart's review papers.
COMPARISONBranded GLP-1s (Mounjaro, Zepbound, Ozempic, Wegovy) are FDA-approved and have full clinical-trial backing. Compounded versions are produced by 503A and 503B compounding pharmacies, were legal during the FDA's official drug-shortage list, and that shortage status changed in 2024 to 2025. Branded is the safer regulatory and quality answer; compounded was the cost-effective answer during the shortage. Check current FDA shortage-list status before making a decision.
COMPARISONTesamorelin (Egrifta) is FDA-approved for HIV-related lipodystrophy with strong trial evidence for visceral-fat reduction. CJC-1295 is a research peptide used in the biohacker GH-axis stack alongside ipamorelin. Tesamorelin is the regulatory-grade molecule with a real prescribing path; CJC-1295 is the operator stack that gets you closer to natural GH pulsing.
COMPARISONBoth target mitochondrial function and aging, but the evidence tier is different. NAD+ (and its precursors NMN and NR) has multiple human RCTs - small ones, but real ones - showing improved insulin sensitivity and elevated tissue NAD+. MOTS-c has one published human trial and a stack of cell and rodent papers. NAD+ is the more evidence-backed daily protocol; MOTS-c is the higher-upside biohacker bet that may not pan out.
COMPARISONRetinol (a vitamin A derivative, not a peptide) has the deepest dermatology trial record - decades of split-face studies showing reduced fine lines, smoother skin, and increased collagen. GHK-Cu is the strongest peer-reviewed peptide for skin, with collagen-density signal in cosmeceutical trials. Most dermatologists run them together. If a reader has to pick one, retinol is the workhorse with the bigger trial record.
COMPARISONCerebrolysin is a porcine-brain peptide cocktail used as a 21-day infusion course for ischemic stroke and TBI, with the CARS and CAPTAIN trial signal behind it. CDP-choline (citicoline) is an oral choline donor with a long Spanish/European trial record for cognitive decline and stroke recovery. Cerebrolysin is the heavier intervention with a stronger acute-stroke signal; citicoline is the daily oral with deeper safety data and easier access.
COMPARISONThese are sister peptides developed by the same Russian institute. Selank is the 'calm' peptide - GABA-modulating, anxiolytic, compared head-to-head to a benzodiazepine in one Russian trial. Semax is the 'focus' peptide - BDNF-upregulating, used as a nasal spray for cognitive support and stroke. Selank for anxiety, Semax for focus and brain insult recovery. Most operators run them on different days for different goals.
COMPARISONSermorelin is the older GHRH (1-29) fragment, FDA-approved in 1990 for growth hormone deficiency before being voluntarily withdrawn for non-safety commercial reasons. CJC-1295 is the modern biohacker version - same 29-amino-acid backbone, modified to extend half-life. Sermorelin gives you cleaner pulsatile GH release; CJC-1295 (no DAC) is more potent and is the molecule operators stack with ipamorelin. CJC-1295 is the better choice for most operators in 2026; sermorelin is still legitimate, just dated.
COMPARISONGlucosamine is an oral supplement with mixed but real evidence for osteoarthritis pain - cheap, accessible, and worth a trial. BPC-157 is a research peptide with strong animal-study evidence for tendon and connective tissue healing but no human RCTs. Glucosamine is the safe first move for joint pain; BPC-157 is the bigger-upside option for tendon and acute soft-tissue injury when glucosamine isn't enough.
COMPARISONGI side effects (nausea, vomiting, constipation, diarrhea) are the dominant issue with both molecules - they happen during dose escalation and usually fade. In SURMOUNT-5 head-to-head, gastrointestinal events causing treatment discontinuation were higher on semaglutide (5.6%) than tirzepatide (2.7%). In broader meta-analyses, tirzepatide has slightly higher overall GI event rates but a lower discontinuation rate. Neither molecule is friendly during the titration phase; both are usually tolerable at maintenance.
COMPARISONSildenafil is the workhorse for erectile dysfunction - it improves blood flow to the penis but does nothing for desire. Bremelanotide (PT-141) is a melanocortin-receptor agonist that acts in the brain on sexual desire and arousal. For mechanical ED that responds to PDE5 inhibitors, sildenafil is the answer. For low desire or PDE5 non-response, bremelanotide is the molecule. They're complementary, not competitors - some men run both.
COMPARISONThese hit different receptors. Tesamorelin is a GHRH analog with FDA approval for HIV lipodystrophy and the strongest VAT-reduction evidence in the GH-axis category. Ipamorelin is a selective ghrelin-receptor agonist with the cleanest side-effect profile of any GH peptide - no cortisol or prolactin spike. Many operators run them together because GHRH + ghrelin agonist produces a larger GH pulse than either alone. Tesamorelin for clinical VAT; ipamorelin for daily GH-axis support.
COMPARISONThe semaglutide shortage was officially resolved by the FDA in February 2025, which closed the legal door on large-scale compounding for semaglutide. 503A pharmacies had until April 22, 2025; 503B outsourcing facilities had until May 22, 2025. After those windows, branded Wegovy (or Ozempic for diabetes) is the legitimate path - and quality control is a non-issue with FDA-supervised cGMP manufacturing. If a reader is still on a compounded protocol in 2026, that should trigger a check on the source pharmacy's legal basis.
COMPARISONBoth are made by Eli Lilly, both treat Type 2 diabetes, and the head-to-head is decisive. Mounjaro (tirzepatide) is the dual GIP/GLP-1 agonist; Trulicity (dulaglutide) is the older GLP-1-only molecule. Mounjaro produces about 2-3x the weight loss and a meaningfully larger A1C drop than Trulicity at maximum doses. Trulicity is older and cheaper; Mounjaro is the heavier hitter. SURPASS-CVOT confirmed cardiovascular non-inferiority in 2025.
COMPARISONBoth are made by Novo Nordisk, both are GLP-1 agonists. Saxenda (liraglutide) is the older daily injection; Ozempic and Wegovy (semaglutide) are the newer once-weekly version. STEP-8 head-to-head: semaglutide produced 15.8% weight loss at 68 weeks vs 6.4% on liraglutide - a 2.5x gap. Semaglutide wins on weight loss, A1C, and adherence (weekly vs daily). Saxenda is older, sometimes cheaper, and the daily-injection cadence is what some patients prefer.
A weekly dispatch on what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.